PHT-1
PT
Menu
Search

Sections

  • Home
  • News
  • Analysis
    • Features
    • Comment
    • Projects
  • Sectors
    • Clinical Trials
    • Drug Manufacturers
    • Therapy Area
      • Cardiovascular
      • Central Nervous System
      • Immunology
      • Infectious Disease
      • Oncology
      • Respiratory
  • Themes
    • Artificial Intelligence
    • Corporate Governance
    • Cloud
    • Cybersecurity
    • Environmental Sustainability
    • Internet of Things
    • Robotics
    • Social Responsibility
    • Covid-19
  • Insights
    • Deals
    • Jobs
    • Filings
    • Patents
    • Social Media
  • Companies
    • Company A-Z
    • Company Categories
    • Products & Services
    • Company Releases
    • White Papers
    • Videos
    • Buyer’s Guides
    • Partner Content
  • Pricing and Market Access
  • Events
  • Reports
  • Premium Insights
  • Excellence Awards
  • Magazine

GlobalData

  • About us
  • Advertise With Us
  • Contact Us
  • Our Marketing Solutions
  • GlobalData Reports
  • Visit GlobalData

From Our Partners

  • Transforming MedTech and Pharma using Software as a Medical Device (SaMD)
  • Accelerating Biopharmaceutical Innovation
  • Accelerating Clinical Trials
  • Precision medicine and digital health innovation for disease diagnosis, care and treatment
  • Enabling process intensification in biopharma manufacturing
  • Specialty drug launch strategy and operations
  • The next chapter of clinical trial services
  • Future Pharma Services
  • Putting quality first in the pharma supply chain
  • Enabling better biopharmaceutical manufacturing
  • Pharmaceutical Grade Silicone Manufacturer
  • Maximising molecule potential
  • News
  • Analysis

    Sections

    • Features
    • Comment
    • Projects

    Latest

    • Why is the healthcare industry hesitant to join the metaverse?
    • Illegal online pharmacies gain traction as regulators lag behind
    • After 2022 interest rate hikes spook investors, pharma M&A to resurge in late 2023
  • Sectors

    Sections

    • Clinical Trials
    • Drug Manufacturers
    • Therapy Area

    Latest

    • Roche Canada and pCPA conclude talks for Vabysmo eye therapy
    • Sun Pharma and Philogen sign licence agreement for anti-cancer therapy
    • Amplo Biotechnology receives NIH-NIAMS grant for gene therapy AMP-201
  • Themes

    Sections

    • Artificial Intelligence
    • Cloud
    • Corporate Governance
    • Cybersecurity
    • Environmental Sustainability
    • Internet of Things
    • Robotics
    • Social Responsibility
    • Covid-19

    Latest

    • ICR and Royal Marsden NHS Foundation Trust open new integrated pathology unit
    • Sanofi deploys Veeva Systems’ solutions to improve quality management
    • Recursion plans $87.5m acquisitions to shore up AI drug discovery
  • Insights

    Sections

    • Deals
    • Jobs
    • Filings
    • Patents
    • Social Media

    Latest

    • Who’s saying what? Microbiome mentions in company filings of pharmaceutical industry decreased by 30% in Q1 2023
    • Who’s saying what? Blockchain mentions in company filings of pharmaceutical industry increased by 17% in Q1 2023
    • Who’s saying what? Orphan Designated Drugs mentions in company filings of pharmaceutical industry decreased by 18% in Q1 2023
  • Companies

    Sections

    • Company A-Z
    • Company Categories
    • Products & Services
    • Company Releases
    • White Papers
    • Videos
    • Buyer’s Guides
    • Partner Content

    Latest

    • Medicines adherence: Overcoming pharma’s biggest barrier to treatment success
    • Untangling the Complexities of Cell and Gene Therapy Clinical Trials: A Supply Chain Perspective 
    • Untangling the Complexities of Cell and Gene Therapy Clinical Trials: A Supply Chain Perspective 
  • Events
  • Reports
  • Premium Insights
PT
  • News
March 1, 2020

Covid-19: What commentators are saying

Live summary of analyst and commentators' responses and updates on the Covid-19 outbreak, updated throughout the day.

By Duncan

Duncan

Free Whitepaper

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
By GlobalData
By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Thank you. Please check your email to download the Whitepaper.

Free Whitepaper

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
By GlobalData
By downloading this case study, you acknowledge that GlobalData may share your information with GlobalData and that your personal data will be used as described in their Privacy Policy Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
Thank you. Please check your email to download the Whitepaper.

Recommended Reports

  • ReportsLogo
    Reports

    LOA and PTSR Model - HCAR-19

    GlobalData
  • ReportsLogo
    Reports

    Clinical Trials - Where are we Headed with COVID-19 Trials?

    GlobalData
View all

Share this article

Recommended Reports

  • ReportsLogo
    Reports

    LOA and PTSR Model - HCAR-19

    GlobalData
  • ReportsLogo
    Reports

    Clinical Trials - Where are we Headed with COVID-19 Trials?

    GlobalData
View all

Duncan

More Relevant

Filings

Who’s saying what? Microbiome mentions in company filings of pharmaceutical industry decreased by 30% in Q1 2023

Filings

Who’s saying what? Blockchain mentions in company filings of pharmaceutical industry increased by 17% in Q1 2023

Filings

Who’s saying what? Orphan Designated Drugs mentions in company filings of pharmaceutical industry decreased by 18% in Q1 2023

Filings

Who’s saying what? Regenerative Medicine mentions in company filings of pharmaceutical industry decreased by 24% in Q1 2023

PharmaceuticalTechnology

The leading site for news and procurement in the pharmaceutical industry

  • About us
  • Advertise with us
  • License our content
  • Contact us
  • Editorial approach
  • Newsletters
  • Our marketing solutions
  • Privacy policy
  • Terms and conditions

Powered by Pharma Tech Logo

© Verdict Media Limited 2023

  • Lost Password Back ⟶
  • Login
  • Register
Lost Password?
Registration is disabled.